Home › Funds › Vestal Point Capital, LP › TRAX
Vestal Point Capital, LP position in TRAX
FIRST TRACKS BIOTHERAPEUTICS · Health Care
Vestal Point Capital, LP reported holding 169,738 shares of TRAX (FIRST TRACKS BIOTHERAPEUTICS) in its Q3 2026 13F filing — a position valued at US$6.0M, representing 0.16% of its reported portfolio and ranking #50 among its reported holdings. Vestal Point Capital, LP has disclosed TRAX holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Vestal Point Capital, LP's TRAX position evolved
Vestal Point Capital, LP first disclosed a stake in TRAX in Q2 2026 at 1,013,000 shares (US$20.4M). Across 2 filings, Vestal Point Capital, LP increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 169,738 shares valued at US$6.0M — a reduction of -843,262 shares quarter over quarter.. Notable position changes include a 83% trim in Q3 2026 (shares rose 31% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2026 | 1.01M | $20.38M | New |
| Q3 2026 | 169.74K | $6.02M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About TRAX and 13F data
TRAX (FIRST TRACKS BIOTHERAPEUTICS) is a Health Care company. 174 other funds we track also report a position in TRAX — the largest reported positions include EcoR1 Capital, LLC (US$112.5M), TCG Crossover Management, LLC (US$102.6M), Affinity Asset Advisors, LLC (US$73.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding TRAX
- EcoR1 Capital, LLC 3.17M sh · $112.50M · Q3 2026
- TCG Crossover Management, LLC 2.90M sh · $102.61M · Q3 2026
- Affinity Asset Advisors, LLC 2.08M sh · $73.72M · Q3 2026
- Sanofi 821.92K sh · $29.13M · Q3 2026
- Trails Edge Capital Partners, LP 814.00K sh · $28.85M · Q3 2026
- Palo Alto Investors LP 741.10K sh · $26.26M · Q3 2026
- STEMPOINT CAPITAL LP 649.92K sh · $23.03M · Q3 2026
- 683 Capital Management, LLC 600.00K sh · $21.26M · Q3 2026
- Sofinnova Investments, Inc. 383.59K sh · $13.59M · Q3 2026
- MPM BioImpact LLC 254.37K sh · $9.02M · Q3 2026
- Boxer Capital Management, LLC 240.00K sh · $8.51M · Q3 2026
- SPHERA FUNDS MANAGEMENT LTD. 160.24K sh · $5.68M · Q3 2026
More on Vestal Point Capital, LP
FAQ
How long has Vestal Point Capital, LP held TRAX?
Vestal Point Capital, LP has disclosed TRAX holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
What is Vestal Point Capital, LP's current position in TRAX?
As of Q3 2026, Vestal Point Capital, LP holds 169.74K shares of TRAX (FIRST TRACKS BIOTHERAPEUTICS), valued at $6.02M, representing 0.16% of its reported portfolio and ranking #50.
Has Vestal Point Capital, LP been buying or selling TRAX?
In the latest 13F filing (Q3 2026), Vestal Point Capital, LP reduced its position in TRAX.
Which other funds hold TRAX?
Other major institutional holders of TRAX include EcoR1 Capital, LLC, TCG Crossover Management, LLC, Affinity Asset Advisors, LLC, among 174 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.